Ankit Mahadevia

Ankit Mahadevia is the current President & CEO of Spero Therapeutics. Ankit has also previously served as the Co-Founder, Acting CEO, and Board of Directors for Rodin Therapeutics, Judo Therapeutics, Journey Colab, and Synlogic, Inc. Ankit Mahadevia has dedicated their career to developing therapies that leverage epigenetic mechanisms for the treatment of unmet medical needs in the neurosciences.

As the Acting CEO of Rodin Therapeutics, Ankit Mahadevia secured equity investment and collaboration with Johnson and Johnson Innovation Center in May 2013. Ankit also raised $12.9MM through a Series A Financing in May 2014 and completed a $500M collaboration with Biogen. Under Ankit's leadership, www.rodintherapeutics.com has become a well-respected name in the development of therapies for unmet medical needs.

As Co-Founder and CEO of Synlogic, Inc., Ankit Mahadevia was inspired by the discoveries of Jim Collins and Tim Lu to develop therapeutic microbes that address high unmet medical needs with the ability to tune therapeutic output based on environmental factors. Ankit secured seed investment from Atlas Venture in Fall 2013 and $30.4M through a Series A led by Atlas Venture, New Enterprise Associates, and the Gates Foundation in July 2014. Ankit also completed a multi-year R & D Collaboration with Abbvie through Synlogic. www.synlogictx.com has become a leading company in next generation synthetic biology thanks to Ankit's dedication and innovative thinking.

Ankit Mahadevia is a medical doctor who graduated from The Johns Hopkins University School of Medicine. Ankit also has an MBA from The Wharton School, and a BA in Economics/Biology from Northwestern University.

Tamara Joseph - Chief Legal Officer, Michael Pucci - Executive Director Early Drug Discovery, and James P. Brady - Chief Human Resource Officer report to Ankit Mahadevia.